Advancis Pharmaceutical (AVNC) Receives FDA Acceptance of Amoxicillin PULSYS NDA
More News related to AVNC
- Advancis Pharmaceutical (AVNC) Concludes Pre-Phase III Meeting with FDA for Development of Keflex PULSYS Product Candidate
- StreetInsider.com Unusual 11 Mid-Day Movers 05/22/2007
- StreetInsider.com Pre-Open Movers 05/22
- Advancis Pharmaceutical (AVNC) Receives FDA Acceptance of Amoxicillin PULSYS NDA
- Advancis Pharmaceutical (AVNC) Announces $24 Million Private Placement of Common Equity
Advancis Pharmaceutical Corporation (Nasdaq: AVNC) announced that the Company's once-daily Amoxicillin PULSYS New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA).
As previously reported, Advancis resubmitted its NDA on March 23, 2007, for its once-daily Amoxicillin PULSYS product for the treatment of adolescents and adults with acute pharyngitis/tonsillitis (commonly referred to as strep throat) via the 505(b)(2) regulatory pathway. The FDA has accepted the Company's NDA for filing and has set a Prescription Drug User Fee Act (PDUFA) target action date for the Company's NDA of January 23, 2008.
Related Categories
FDAHot List
Stocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
